Gastroenterology
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a key area of focus for Johnson & Johnson. Since introducing the first anti-tumor necrosis factor (TNF)-alpha therapy to the market in 1999 for the treatment of Crohn’s disease¹ ², we have changed the IBD treatment paradigm and remain focused in this disease area.
Our unique clinical and research capabilities and expertise, combined with a track record of operational excellence and success, have fostered a robust, prioritized pipeline and strategy for the future. With the introduction of biologics with new mechanisms of action, and investment in predictive biomarkers, Johnson & Johnson remains committed to developing differentiated treatments for both patients living with IBD and healthcare professionals.
Immunology starts with J - Switzerland
Why? Because Switzerland is an important location for Johnson & Johnson, with over 4,700 dedicated employees.³ Did you know that our Immunology Products, among others, are manufactured in Schaffhausen?
We're thinking further: Through our Safe Returns program, we offer patients a simple and safe way to properly dispose of used syringes and pens. But it doesn't stop there – we're working hard to return these materials to the cycle. This is how we take responsibility – for people's health and the protection of our environment.
1. Fachinformation Remicade®. Stand März 2025. www.swissmedicinfo-pro.ch.
2. Liste Swissmedic «Zugelassene Arzneimittel» Humanarzneimittel (Stand 31.01.2026) auf https://www.swissmedic.ch/swissmedic/de/home/services/listen_neu.html#-257211596 (zuletzt aufgerufen am 23.02.2026)
3. Johnson & Johnson in der Schweiz. Unsere Standorte. https://www.jnj.com/CH/de/standorte (Stand 18.02.2026)
Remicade® (Infliximab). Janssen-Cilag, a Johnson&Johnson company, Gubelstrasse 34, 6300 Zug. Abgabekategorie A. Weitere Informationen auf www.swissmedicinfo-pro.ch.
Documents:
Tremfya